

North Yorkshire & York Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on the 2nd February 2022

Classification of products:

- G** **Green drug** - Can be initiated and prescribed in all care settings **○**- Second line / alternative green drug
- ASR** **Amber Specialist Recommendation drug** - Can be recommended by a specialist for initiation in primary care
- ASI** **Amber Specialist Initiation drug** – Initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.
- ASC** **Amber Shared Care drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care
- R** **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as “hospital only” drugs
- BLACK Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within North Yorkshire & York.
- GREY Not Reviewed** - Drugs that haven't been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in North Yorkshire & York.



Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
Nil this month				
2) New Requests				
Lurasidone 18.5 mg, 37 mg and 74 mg tablets For the treatment of schizophrenia in adults and adolescents aged 13 years and over.			✓	Deferred decision to get more information on potential patient numbers and cost impact for North Yorkshire and Vale of York CCGs given the big price differential to aripiprazole
Pancrex V Powder To be used in patients with pancreatic insufficiency who are unable to take capsules orally and/or on enteral feed and nil by mouth.	✓ G			Approved as 3rd choice pancreatin supplement for use only in patients with feeding tubes. Others products cannot be administered to feed or via feeding tube
Nutrizym 22 Capsules To be used in patients with pancreatic insufficiency who are unable to take Creon capsules orally due to side effects	✓ G			2 nd choice in patients who are unable to take Creon capsules orally due to side effects. If patients do not then tolerate Nutrizym 22 Capsules they should return to taking Creon capsules on the basis of cost.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
3) New formulations & extensions to use				
Nil this month				
5) Products considered by NICE				
TA748: Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA749: Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal)	✓ BLACK			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA750: Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal)	✓ BLACK			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA751: Dupilumab for treating severe asthma with type 2 inflammation	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner. Tertiary centre provided.
TA752: Belimumab for treating active autoantibody-positive systemic lupus erythematosus	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA753: Cenobamate for treating focal onset seizures in epilepsy	✓ ASI			The formulary will reflect the TAG – CCGs are the responsible commissioner. Only to be initiated in or on recommendation of a tertiary epilepsy service. Still to confirm if York Trust has a tertiary epilepsy service. Confirmed that Harrogate Trust do not have a tertiary epilepsy service so will not be initiating.
TA754: Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA755: Risdiplam for treating spinal muscular atrophy	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA756: Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
6) Appeals against earlier decisions by the APC				
None				
7) Miscellaneous formulary decisions by the APC				
Neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19	✓ R			Added to the formulary as RED drugs as per NHSE commissioning policy
New name for Biosimilar Insulin Lispro Sanofi	✓			Brand name on formulary updated to Admelog®.
Formulary status of alcohol dependence drugs for VoY CCG – Acamprosate and Disulfiram	✓ R in York for patients attending Spectrum ASI for patients attending Horizons in North Yorkshire			Agreed RAG status on formulary to reflect current commissioning arrangements via Spectrum in VoY CCG. Already has RAG status for patients via Horizons in North Yorkshire County Council area.

The following guidelines were presented to and approved at the February 2022 meeting of the APC:

- Guidelines for recognition and management of non- IgE cow's milk allergy in children
- Biologics pathway for Psoriatic Arthritis – updated to include upadacitinib.

The following shared care guidelines were presented to and approved at the February 2022 meeting of the APC:

- Nil this month.

Other documents presented to and approved at the February 2022 meeting of the APC:

- Nil this month.